Powered by
MOMENTUM
MEDIA
Global law firm Norton Rose Fulbright has strengthened its corporate practice by appointing a veteran partner from rival BigLaw firm Baker McKenzie.
Kate Jefferson (pictured) has joined Norton Rose Fulbright’s corporate practice as a partner, taking up the new role in the global law firm’s Sydney office.
Before joining Norton Rose Fulbright, Jefferson spent more than 21 years at rival BigLaw firm Baker McKenzie, including the past 13 years as a partner.
During her time at Baker McKenzie, Jefferson held a number of senior leadership positions within its healthcare and life sciences practice, including co-head of its Australian healthcare and life sciences group and a member of its Asia-Pacific healthcare and life sciences steering committee.
She brings more than two decades of experience advising clients on high-profile, cross-border M&A and capital markets transactions across Australia and the broader Asia-Pacific region.
Her extensive practice spans private and public M&A, joint ventures, carve-outs, corporate reorganisations and equity capital raisings, as well as advising clients on Australian Securities Exchange (ASX) governance requirements.
Norton Rose Fulbright’s global managing partner and managing partner for Europe, Middle East and Asia Pacific, Peter Scott, said Jefferson’s cross-border M&A expertise and deep sector knowledge would further strengthen the firm’s growing Asia-Pacific offering.
“Kate’s history of advising clients on complex corporate and M&A transactions across Asia-Pacific will strengthen our cross-border corporate offering and our broader Europe, Middle East and Asia-Pacific (EMEAPAC) business,” Scott said.
“Her particular focus on the life sciences and healthcare industries dovetails with our strong global presence in these areas, as does her support of clients in technology and consumer markets.”
Speaking about her new role, Jefferson shared that the firm’s global reach, established Australian corporate practice, and growth ambitions across the Asia-Pacific region were key factors behind her move.
“The combination of Norton Rose Fulbright’s strong global platform, well-established Australian corporate practice and ambition to grow in Asia-Pacific was a major drawcard for me,” Jefferson said.
She added that the move would provide an opportunity to continue advising clients across several key sectors while collaborating with the firm’s broader corporate, regulatory and intellectual property teams.
“I look forward to the opportunity to continue my support of clients across the life sciences and healthcare, technology and consumer markets industries, working alongside the firm’s corporate, regulatory and intellectual property partners,” Jefferson said.
